Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2024—Verichem Laboratories offers a multilevel set of clinical reference materials intended for the calibration verification of clinical systems testing for total protein and albumin in urine and cerebrospinal fluid samples. The liquid-stable and ready-to-use materials are suitable for use with turbidimetric and colorimetric test methods and incorporate human protein components.
April 2024—Bayer and Thermo Fisher Scientific announced that they will develop next-generation sequencing–based companion diagnostic assays to help identify patients who may benefit from Bayer’s precision cancer therapies. The assays will be developed using Thermo Fisher’s Oncomine Dx Express test on the Ion Torrent Genexus Dx system. The Genexus Dx instrument and Oncomine Dx Express test are CE-IVD marked and only available in countries that accept the CE mark.
April 2024—Technoclone and its distributor in the United States, DiaPharma Group, announced that the FDA has granted de novo classification for the Technozym ADAMTS13 Activity ELISA. The assay is intended for the qualitative determination of ADAMTS13 activity in platelet poor human citrated plasma and indicated for use in conjunction with other clinical and laboratory findings as an aid in diagnosing thrombotic thrombocytopenic purpura in adult and pediatric patients being evaluated for thrombotic microangiopathy.
March 2024—The Matrix Plus chemistry reference kit and standalone, ultra-high Matrix Plus level F for the calibration verification testing of creatinine assays by enzymatic and colorimetric methods are available from Verichem Laboratories. The ready-to-use reference materials offer constant protein content and pH across all concentration levels. The five-level Matrix Plus kit and level F feature a creatinine range from 0.2 mg/dL to 30.0 mg/dL and are intended to be treated as patient specimens. Shelf life and open-vial stability are 21 months from the manufacturing date.
March 2024—Bio-Rad Laboratories has published the third workbook in a P.A.C.E.-approved series designed to provide lab professionals with the training and education needed to maintain reliable test results. “Quality Control Process Optimization with Cost of Quality Application” focuses on a practical approach of cost of quality to the laboratory workflow process of quality control. After using the workbook, laboratorians will be able to construct a basis worksheet to calculate the failure costs of a selected failed laboratory process.
March 2024—Agilent Technologies announced an agreement with Incyte to develop companion diagnostics in hematology and oncology. The agreement enables Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of companion diagnostics in the United States and Europe.
March 2024—Innovative Lab Solutions announced the appointment of Bridget Ketron as its vice president of solutions. With a focus on enhancing efficiency, boosting cash collections, and ensuring compliance, Ketron will play a key role in driving the company’s growth and strategic partnerships.
March 2024—Avails Medical announced it has received FDA 510(k) clearance for its Equant system, an automated lab inoculation preparation system that consists of a single module instrument that holds a cuvette with an electrical sensor. It is intended for use with positive blood cultures samples for direct antimicrobial susceptibility testing without the traditional overnight subculture. The system works by preparing samples for direct susceptibility testing by manual agar disk diffusion.
March 2024—Randox has released its female bladder cancer array, designed to help clinicians stratify patients presenting with hematuria. The array detects interleukin-12p70, interleukin-13, midkine, and clusterin from a single urine sample to determine an individual’s biomarker risk score. A person’s risk for developing bladder cancer is determined by combining the biomarker risk score with clinical risk scores generated using the company’s algorithms.
March 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about $940 million) in cash, excluding EliTech’s clinical chemistry business. Bruker expects to close the transaction in the second quarter of this year.
